Hunan Huateng Pharmaceutical Co. Ltd. articles

Huateng Pharma, a leading Contract Development and Manufacturing Organization (CDMO), is proud to announce the launch of its latest product, Piroctone Olamine (CAS: 68890-66-4). This addition underscores Huateng Pharma’s commitment to providing high-quality pharmaceutical ingredients to meet the diverse needs of the global health and personal care industries.

Piroctone Olamine is a highly effective antifungal

Huateng Pharma, a leading supplier of high-quality ingredients for the pharmaceutical and cosmetic industries, is proud to announce its range of novel ingredients designed for both commodities and cosmetics. The company is committed to delivering excellence from lab to commercial scale, ensuring the highest standards of quality and performance.

1. Tetrahydrocurcumin (CAS No. 36062-04-1): Antioxidant and Skin-Whitening Powerhouse

Huateng Pharma introduces

Minoxidil was first introduced by Upjohn Company of the United States, and was first used as an oral drug for the treatment of refractory hypertension in the 1970s. In later clinical applications, doctors observed hair regrowth and generalized excessive hair in balding patients, which led to the development of minoxidil preparations.

Minoxidil can increase local blood supply, stimulate the proliferation and differentiation of hair follicle epithelial cells, so as to promote hair growth

Diabetes is a chronic disease that affects more than 540 million people worldwide and is one of the leading causes of death and disability worldwide. In China, there are more than 114 million adults with diabetes, accounting for about a quarter of the world's diabetes patients. With the change of living and eating habits, diabetes has become the third major factor affecting human health after cardiovascular and cerebrovascular diseases and malignant tumors, bringing a heavy physical and menta

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. In 2018, it is estimated that 627,000 women died from breast cancer – that is approximately 15% of all cancer deaths among women. While breast cancer rates are higher among women in more developed regions, rates are increasing in nearly every region globally.

The majority of patients with metastatic breast cancer (